-transparent.png){kind=logo}
The presence of specific Factor VIII/von Willebrand factor (FVIII/vWF) binding sites on human platelets has been demonstrated by using 125I-FVIII/vWF and washed human platelets. Binding is ristocetin-dependent and increases in proportion to the concentration of ristocetin from 0.2 to 1 mg/ml. Binding of 125I-FVIII/vWF to platelets can be competitively inhibited by unlabeled human or bovine FVIII/vWF, but not by human thrombin, fibrinogen, alpha 2-macroglobulin, equine collagen, or a lectin of Ricinus communis. Scatchard analysis of binding data indicated that the dissociation constant of FVIII/vWF receptors is 0.45--0.5 nM. There are 31,000 binding sites per platelet at 1 mg/ml of ristocetin concentration. The optimal pH range for binding is from 7.0 to 7.5. At a concentration of 2 mM, EGTA inhibits 86% of the binding; however, 20 mM of Ca++, Mg++, or EDTA have little effect. Binding sites for FVIII/vWF were found only on platelets, and no significant binding was detected with human erythrocytes or polymorphonuclear leukocytes.
K J Kao, and
S V Pizzo, and
P A McKee
August 1982,
Blood,
K J Kao, and
S V Pizzo, and
P A McKee
January 1980,
Blood,
K J Kao, and
S V Pizzo, and
P A McKee
June 1975,
Thrombosis research,
K J Kao, and
S V Pizzo, and
P A McKee
June 1985,
Thrombosis and haemostasis,
K J Kao, and
S V Pizzo, and
P A McKee
September 1984,
Thrombosis research,
K J Kao, and
S V Pizzo, and
P A McKee
June 1986,
Blut,
K J Kao, and
S V Pizzo, and
P A McKee
January 1983,
Biology of the cell,
K J Kao, and
S V Pizzo, and
P A McKee
September 1991,
The Journal of biological chemistry,
K J Kao, and
S V Pizzo, and
P A McKee
October 1990,
Danish medical bulletin,
K J Kao, and
S V Pizzo, and
P A McKee
August 1981,
Blood,
